Tqa3526 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎［原発性胆汁性肝硬変 (~2017.3)］ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04278820 (ClinicalTrials.gov) | March 20, 2020 | 18/1/2020 | A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) | A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of TQA3526 in the Treatment of Naive or Previously Treated PBC Patients | Primary Biliary Cirrhosis | Drug: TQA3526;Drug: Placebo to match TQA3526 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NULL | Not yet recruiting | 18 Years | 70 Years | All | 130 | Phase 2 | China |